Opthea Limited (OPT)

Market Cap	229.96M
Revenue (ttm)	138,198
Net Income (ttm)	-64.46M
Shares Out	58.36M
EPS (ttm)	-1.47
PE Ratio	n/a
Forward PE	6.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,952
Open	3.91
Previous Close	3.93
Day's Range	3.91 - 3.96
52-Week Range	3.91 - 8.50
Beta	0.31
Analysts	Buy
Price Target	9.16 (+132.49%)
Earnings Date	n/a

About OPT

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Country: Australia
• Stock Exchange: NASDAQ
• Ticker Symbol: OPT

Financial Performance

In 2022, Opthea's revenue was 199,005, an increase of 108.24% compared to the previous year's 95,563. Losses were -92.82 million, 104.7% more than in 2021.

Financial numbers in AUD

Analyst Forecast

According to 9 analysts, the average rating for OPT stock is "Buy." The 12-month stock price forecast is $9.16, which is an increase of 132.49% from the latest price.

Price Target

$9.16

(132.49% upside)

Analyst Consensus: Buy